临床游离DNA筛查结果中胎儿分数较低与妊娠期高血压疾病风险增加相关
该回顾性队列研究纳入534例单胎妊娠并接受cfDNA筛查的女性,以胎儿分数(FF)10%为界分为低FF组(<10%,N=259)和高FF组(≥10%,N=275)。低FF组妊娠期高血压疾病发生率显著更高(32.0% vs 11.6%,P<0.001),发生HDP的比值比为2倍(P=0.006);复合母体不良结局发生率亦更高(51.4% vs 30.2%,P<0.001),比值比为1.7倍(P=0.014)。结论认为cfDNA筛查报告的低FF与HDP风险增加相关,有潜力作为预测标志物。
要点
- 低FF组(<10%)妊娠期高血压疾病发生率为32.0%,高于高FF组(≥10%)的11.6%(P<0.001)。
- 低FF组发生HDP的比值比为2倍(P=0.006),复合母体不良结局比值比为1.7倍(P=0.014)。
- cfDNA筛查报告中的FF有潜力作为HDP及不良妊娠结局的预测标志物。
核心结论
- cfDNA筛查中低胎儿分数与妊娠期高血压疾病风险增加相关。
- cfDNA筛查报告中的胎儿分数有潜力作为HDP及不良结局发生的预测标志物。
研究设计与样本
- 回顾性队列研究,纳入534例接受cfDNA筛查的单胎妊娠女性,依据受试者工作特征曲线分析确定的FF阈值10%分为低FF组(<10%,N=259)和高FF组(≥10%,N=275)。
主要发现
- 低FF组妊娠期高血压疾病发生率为32.0%,高FF组为11.6%(P<0.001)。
- 低FF组发生HDP的比值比为2倍(P=0.006)。
- 低FF组复合母体不良结局发生率为51.4%,高FF组为30.2%(P<0.001)。
- 低FF组发生任一不良产科结局的比值比为1.7倍(P=0.014)。
关键数值与推荐
- FF阈值10%由受试者工作特征曲线分析确定,用于区分低FF组(<10%)和高FF组(≥10%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate if fetal fraction (FF) reported on cell-free DNA (cfDNA) screening is a marker for adverse obstetric outcomes. METHODS: We retrospectively reviewed medical records from a cohort of women with singleton pregnancies who had cfDNA screening. We evaluated if reported FF could predict the following pregnancy complications: hypertensive disorders of pregnancy (HDP), fetal growth restriction, preterm delivery, gestational diabetes mellitus, or a composite maternal morbidity, defined as the presence of at least one of these outcomes. RESULTS: Receiver operating curve analysis was performed on FF from 534 women to define the FF that differentiated a low FF group (<10%; N = 259) and a high FF group (≥10%; N = 275). Hypertensive disorders of pregnancy were more common for women in the low FF group (32.0% vs. 11.6% and p < 0.001), who had a two-fold odds of developing HDP (p = 0.006). Composite maternal morbidity was also more common for women in the low FF group (51.4% vs. 30.2% and p < 0.001), who had a 1.7-fold odds of developing any of the adverse obstetrical outcomes (p = 0.014). CONCLUSION: We found that low FF on cfDNA screening is associated with an increased risk of HDP. Fetal fraction reported that cfDNA screening reports have potential as a predictive marker for the development of HDP and adverse outcomes.
引用
- Madala D, Maktabi MA, Sabbagh R, et al. Lower fetal fraction in clinical cell-free DNA screening results is associated with increased risk of hypertensive disorders of pregnancy. Prenat Diagn. 2022. PMID: 35943975. doi:10.1002/pd.6221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。